The role of salt inducible kinases in renal PTH action
盐诱导激酶在肾 PTH 作用中的作用
基本信息
- 批准号:10207599
- 负责人:
- 金额:$ 41.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcuteAdaptor Signaling ProteinAdenineAutoimmuneBindingBiologyBloodBone DiseasesBone ResorptionBypassCYP27B1 geneCalciumCellsChronicChronic Kidney FailureCyclic AMPCyclic AMP-Dependent Protein KinasesDataDietDiseaseEndocrineEnzymesEpithelial CellsEventExcretory functionFamilyFamily memberFutureGene ExpressionGenesGenetic TranscriptionGoalsHomeostasisHormonalHormone ResponsiveHormone useHormonesHumanIn VitroInflammatoryInjury to KidneyInorganic Phosphate TransporterIonsKidneyKidney DiseasesKnock-outKnowledgeLightLinkMediatingMediator of activation proteinMetabolismMineralsMissionModelingModificationMolecularMusNational Institute of Diabetes and Digestive and Kidney DiseasesNephronsNucleic Acid Regulatory SequencesOralOrganOrganoidsOsteocytesOsteogenesisOsteoporosisPTH geneParathyroid Hormone ReceptorPathway interactionsPharmaceutical PreparationsPhenotypePhosphoric Monoester HydrolasesPhosphorylationPhosphorylation InhibitionPlayPost-Translational RegulationProductionProtein IsoformsProtein Phosphatase 2A Regulatory Subunit PR53ProteinsProximal Kidney TubulesReceptor ActivationRegulationRegulatory PathwayResearchRoleSerumSignal PathwaySignal TransductionTestingTherapeuticTherapeutic UsesTissuesTranscriptional ActivationUnited States National Institutes of HealthUpstream EnhancerVitamin Dbonebone healthbone massbrush border membranecalcium metabolismchromatin immunoprecipitationexperimental studyhormonal signalshormone resistancehuman diseasein vivoinhibitor/antagonistinorganic phosphatekidney cellkinase inhibitormouse modelnovelnovel strategiesnovel therapeutic interventionreceptorrenal epitheliumsalt-inducible kinaseskeletalskeletal disordersmall moleculesmall molecule inhibitortherapeutic targettranscription factortranscriptometranscriptome sequencingtreatment effectuptakeurinary
项目摘要
Project Summary
Parathyroid hormone (PTH) maintains mineral ion homeostasis by interacting with the PTH/PTHrP receptor to
induce transcriptional and post-transcriptional modifications in target tissues. PTH stimulates resorption of the
mineral matrix in bone, and increases production of active vitamin D, calcium reabsorption, and phosphate
excretion in the kidneys. Despite the central role of PTH as a regulatory hormone, many of the downstream
intracellular target molecules that orchestrate PTH signaling events have yet to be identified. Characterization of
these pathways will expand current knowledge of the mechanisms governing mineral homeostasis, and suggest
new therapeutic strategies to counteract or restore PTH action in skeletal and renal disease. Recently, salt-
inducible kinases (SIKs) were identified as intracellular mediators of PTH signaling in osteocytes, and small-
molecule inhibitors of SIKs were found to mimic PTH action on bone in vivo. The objective of this proposal is to
explore whether analogous SIK-dependent PTH signaling pathways are active in the kidney. Aim 1 of this
proposal will explore the molecular mechanisms through which PTH/SIK signaling regulates CYP27B1
expression. In renal cells, human kidney organoids, and mice, both PTH and the SIK inhibitor YKL-05-099
increase expression of CYP27B1, the enzyme that converts inactive vitamin D to its active form. In renal cells,
PTH treatment results in decreased phosphorylation of SIK3 substrate CRTC2. The remaining intermediaries of
the PTH/SIK/CYP27B1 pathway will be characterized using in vitro experiments targeting molecules upstream
and downstream of SIK in renal cells and organoids. Chromatin Immunoprecipitation of CRTC family members
will identify the regulatory regions necessary for CYP27B1 transcriptional activation by PTH/SIK. Aim 2 will
define the role of PTH/SIK signaling in renal phosphate reabsorption. Mice treated with PTH or YKL-05-099 have
decreased serum phosphate levels, and YKL-05-099 treatment decreases phosphate transporter Npt2a
localization to the renal brush border membrane. These mice will be tested to confirm that SIK inhibition induces
phosphaturia in vivo. Three SIK family members will be knocked out in renal epithelial cells and their effect on
phosphate uptake assessed. Aim 3 will characterize the phenotype of mice lacking renal SIK1 and SIK3, and
explore the therapeutic potential of small molecule SIK inhibitors in CKD-MBD. The experiments described here
explore a novel role for SIKs in regulating PTH signaling in the kidney. In addition, mouse models developed for
this project will help to shed light on the crucial bone/kidney regulatory axis that controls mineral homeostasis
and bone health. This project also offers a novel application for SIK inhibitors, a class of drug currently studied
for their application in autoimmune and other inflammatory disorders, as treatment in later stages of chronic
kidney disease (CKD) and other disorders of mineral ion homeostasis that are unresponsive to PTH.
项目摘要
甲状旁腺激素(PTH)通过与PTH/PTHrP受体相互作用维持矿物质离子动态平衡
在靶组织中诱导转录和转录后修饰。甲状旁腺激素刺激心脏的吸收
骨骼中的矿物质基质,并增加活性维生素D、钙重吸收和磷酸盐的产生
肾脏的排泄物。尽管甲状旁腺激素作为调节荷尔蒙的核心作用,但许多下游
协调甲状旁腺素信号事件的细胞内靶分子尚未确定。特征描述
这些途径将扩大目前关于矿物质动态平衡机制的知识,并提示
新的治疗策略,以抵消或恢复甲状旁腺素在骨骼和肾脏疾病中的作用。最近,盐-
诱导蛋白激酶(SIKs)被认为是骨细胞甲状旁腺素信号的细胞内介质,而小分子蛋白激酶(SIKs)是骨细胞甲状旁腺素信号转导的调节因子。
SIKS的分子抑制剂在体内被发现模拟甲状旁腺激素对骨的作用。这项建议的目的是
探讨类似的依赖SIK的甲状旁腺素信号通路在肾脏中是否活跃。目标1
提案将探索PTH/SIK信号调节CYP27B1的分子机制
表情。在肾细胞、人肾器官和小鼠中,PTH和SIK抑制剂YKL-05-099
增加细胞色素P27B1的表达,这是一种将非活性维生素D转化为活性形式的酶。在肾脏细胞中,
PTH处理导致SIK3底物CRTC2的磷酸化水平降低。剩余的中介人
PTH/Sik/CyP27B1途径将通过针对上游分子的体外实验来表征
在SIK下游的肾细胞和类器官中。CRTC家族成员的染色质免疫沉淀
将确定PTH/SIK转录激活所需的调节区。目标2将
明确PTH/SIK信号在肾脏磷酸盐重吸收中的作用。PTH或YKL-05-099处理的小鼠
降低血磷水平,YKL-05-099治疗降低磷酸盐转运体Npt2a
定位于肾刷状缘膜。将对这些小鼠进行测试,以确认SIK抑制会诱导
体内的磷酸尿症。三个SIK家族成员将在肾上皮细胞中被敲除及其对
磷酸盐吸收评估。目的3将描述缺乏肾脏SIK1和SIK3的小鼠的表型,以及
探讨小分子SIK抑制剂在CKD-MBD中的治疗潜力。这里描述的实验
探索SIKS在调节肾脏甲状旁腺激素信号转导中的新作用。此外,为
该项目将有助于阐明控制矿物质动态平衡的关键骨骼/肾脏调节轴。
和骨骼健康。该项目还为目前正在研究的一类药物SIK抑制剂提供了一种新的应用
在自身免疫和其他炎症性疾病中的应用,作为慢性疾病晚期的治疗
肾脏疾病(CKD)和其他对甲状旁腺激素无反应的矿物质离子稳态紊乱。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Mannstadt其他文献
Michael Mannstadt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Mannstadt', 18)}}的其他基金
Mode of Action of GCM2, the Essential Parathyroid Transcription Factor
GCM2(必需的甲状旁腺转录因子)的作用方式
- 批准号:
9199579 - 财政年份:2014
- 资助金额:
$ 41.09万 - 项目类别:
Mode of Action of GCM2, the Essential Parathyroid Transcription Factor
GCM2(必需的甲状旁腺转录因子)的作用方式
- 批准号:
9407219 - 财政年份:2014
- 资助金额:
$ 41.09万 - 项目类别:
Dominant-negative GCMB mutations cause hypoparathyroidism
显性阴性 GCMB 突变导致甲状旁腺功能减退症
- 批准号:
7874711 - 财政年份:2008
- 资助金额:
$ 41.09万 - 项目类别:
Dominant-negative GCMB mutations cause hypoparathyroidism
显性阴性 GCMB 突变导致甲状旁腺功能减退症
- 批准号:
8281495 - 财政年份:2008
- 资助金额:
$ 41.09万 - 项目类别:
Dominant-negative GCMB mutations cause hypoparathyroidism
显性阴性 GCMB 突变导致甲状旁腺功能减退症
- 批准号:
7513972 - 财政年份:2008
- 资助金额:
$ 41.09万 - 项目类别:
Dominant-negative GCMB mutations cause hypoparathyroidism
显性阴性 GCMB 突变导致甲状旁腺功能减退症
- 批准号:
7658864 - 财政年份:2008
- 资助金额:
$ 41.09万 - 项目类别:
Dominant-negative GCMB mutations cause hypoparathyroidism
显性阴性 GCMB 突变导致甲状旁腺功能减退症
- 批准号:
8101915 - 财政年份:2008
- 资助金额:
$ 41.09万 - 项目类别:
The role of salt inducible kinases in renal PTH action
盐诱导激酶在肾 PTH 作用中的作用
- 批准号:
10434876 - 财政年份:1997
- 资助金额:
$ 41.09万 - 项目类别:
The role of salt inducible kinases in renal PTH action
盐诱导激酶在肾 PTH 作用中的作用
- 批准号:
10656318 - 财政年份:1997
- 资助金额:
$ 41.09万 - 项目类别:
The role of salt inducible kinases in renal PTH action
盐诱导激酶在肾 PTH 作用中的作用
- 批准号:
9793439 - 财政年份:1997
- 资助金额:
$ 41.09万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 41.09万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 41.09万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 41.09万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 41.09万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 41.09万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 41.09万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 41.09万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 41.09万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 41.09万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 41.09万 - 项目类别:
Operating Grants